Background. Varieties of methods have been suggested for rapid detection of carbapenem resistance in gram-negative rods. However, their clinical application is hampered by either detection of only selected resistance mechanisms or labor-intensive processing. This study investigated a novel easy-to-perform, mechanism-independent method for detection of carbapenem resistance in Pseudomonas aeruginosa.
Analytical Performance Characteristics of the
Background. The Accelerate Pheno™ system is a novel fast diagnostic that significantly reduces the time to ID and AST for GNB and ID of Candida spp. bloodstream infections, with the potential to impact clinical outcomes. Prospective clinical trials are needed to evaluate the impact of this new system on clinical outcomes and antimicrobial stewardship.
Methods. From April 14, 2016 to March 3, 2017, blood cultures from unique patients in the emergency department and medical intensive care units at BarnesJewish Hospital that signaled positive and were Gram-stain positive for GNB or Candida spp. were eligible. AXDX testing using pre-FDA cleared software (v1.0) was conducted in parallel with standard-of-care (SOC) diagnostic testing. SOC AST was Kirby-Bauer Disk Diffusion and/or Etest ® and SOC ID was the VITEK ® MS system. Results. Of 341 screened blood culture bottles, 123 met inclusion criteria; 101 (82%) were on-panel for ID with AXDX, 88 GNB (7 species) and 13 C. glabrata or C. albicans. Non-panel organisms were other Candida spp. in 36.4% (8/22), other GNB in 54.5% (12/22), and Gram-positive bacteria in 9.1% (2/22). For on-panel organisms with MALDI-TOF as the gold standard, sensitivity for ID of GNB was 95.4%, specificity 99.9%. One each of the following was missed: E. coli, Klebsiella spp., Proteus spp., and P. aeruginosa. Of missed GNB, all except P. aeruginosa were part of polymicrobial cultures. For on-panel Candida spp., sensitivity of ID was 91.7%, specificity 99%. Overall category agreement (CA) for GNB AST between AXDX and SOC was 91.4%. CA was lowest for ampicillin-sulbactam (69.1%), piperacillin-tazobactam (85.7%), ceftazidime (86.4%), and tobramycin (87%). All other antibiotics had CA >92%. Very major errors were logged for 0.1% (n = 1 for tobramycin), major errors for 1.5% (n = 13), and minor errors for 6.3% (n = 53). There were 13 assay failures, including 10 failed AST, 2 failed ID, and 1 instrument technical failure. The most common reason for failure was too few clones of bacteria for analysis using AXDX (9/13, 69.2%).
Conclusion. The Accelerate Pheno
TM system is a novel fast diagnostic with high sensitivity and specificity for the ID and AST of GNB and ID of Candida spp. bloodstream infections that are on-panel. Methods. BC bottles were inoculated with 10ml of fresh whole blood collected from healthy volunteers. The blood was spiked to achieve mean peak, midpoint, and trough concentrations of MEM (40, 20 and 5 µg/mL), C/T (150, 50, and 8 µg/mL), and CZA (90, 25, and 10 µg/mL), respectively. A control bottle containing no antibiotic was included. BC bottles were then inoculated with 7-30 colony forming units (CFU)/bottle of either a MEM susceptible (MEM-S) (MIC = 0.5 µg/mL, C/T = 0.5 µg/ mL, CZA = 2 µg/mL) or MEM resistant (MEM-R) PSA (MIC = 8 µg/mL, C/T = 4 µg/ mL, CZA = 8 µg/mL) isolate. Matching bottles were entered into a BacT/ALERT ® -3D detection instrument and a standard incubator at 37° C for up to 72h. Each series was conducted in duplicate. TTD was measured in the detection instrument, and CFUs were counted at 0, 4, 12, 24, 36, 48, 60, and 72h in incubated bottles.
Results. Control PSA grew to 7.4 × 10 8 /mL with a TTD of 15.5-19.5 hours. Both PSA grew in the presence of MEM trough concentrations with TTD of 21.3 ± 3.3 hours. However, midpoint and peak concentrations inhibited growth of the MEM-S PSA. The MEM-R PSA grew in the presence of all MEM concentrations, with a TTD of 18.6 ± 0.5 hours. Both PSA grew in the presence of C/T trough concentrations with TTD of 23.0 ± 2.6 hours, but were inhibited by midpoint and peak C/T concentrations. For CZA, both PSA grew in the presence of trough concentrations with TTD of 20.1 ± 1.9 hours. Peak CZA concentrations inhibited growth of both PSA, while midpoint concentrations inhibited growth of the MEM-S isolate.
Conclusion. These are the first data to show that BacT/ALERT BC bottles containing ABA may not sufficiently inactivate achievable concentrations of MEM, C/T or CZA, which could result in false negatives. In patients already receiving one of these antibiotics, BCs should be collected just prior to the next dose to increase the probability of PSA detection.
Disclosures. All authors: No reported disclosures. Saturday, October 7, 2017: 12:30 PM Background. At the National Center for Global Health and Medicine (NCGM; Tokyo, Japan), prevalence of penicillin-susceptible Staphylococcus aureus isolates with penicillin G minimum inhibitory concentration (MIC) ≤ 0.12 μg/mL comprised 31% of isolates (733/2387) collected between 2013 and 2015; this is higher than those reported in previous studies. However, little is known about the prevalence of β-lactamase production in penicillin-susceptible S. aureus isolates under high-susceptibility conditions.
Molecular Epidemiology of β-lactamase Production in Penicillin-
Methods. We analyzed S. aureus isolates with penicillin G MIC ≤ 0.12 μg/mL that were recovered from in-/outpatients between 2016 and 2017. β-Lactamase production was detected by nitrocefin-based and Clinical and Laboratory Standards Institute penicillin zone-edge testing (using 10-U penicillin disc) and blaZ PCR.
Results. A total of 108 isolates were analyzed, predominantly originating from the lower respiratory tract (56%), abscesses (9%), upper respiratory tract (8%), and
